U.S. Markets close in 5 hrs 35 mins
  • S&P 500

    4,247.58
    -7.57 (-0.18%)
     
  • Dow 30

    34,268.80
    -124.95 (-0.36%)
     
  • Nasdaq

    14,114.67
    -59.47 (-0.42%)
     
  • Russell 2000

    2,320.46
    -5.69 (-0.24%)
     
  • Crude Oil

    71.76
    +0.88 (+1.24%)
     
  • Gold

    1,863.50
    -2.40 (-0.13%)
     
  • Silver

    27.69
    -0.35 (-1.24%)
     
  • EUR/USD

    1.2127
    +0.0004 (+0.0364%)
     
  • 10-Yr Bond

    1.5060
    +0.0050 (+0.33%)
     
  • Vix

    16.91
    +0.52 (+3.17%)
     
  • GBP/USD

    1.4076
    -0.0032 (-0.2280%)
     
  • USD/JPY

    110.1310
    +0.0700 (+0.0636%)
     
  • BTC-USD

    40,103.86
    -783.05 (-1.92%)
     
  • CMC Crypto 200

    999.78
    -10.82 (-1.07%)
     
  • FTSE 100

    7,180.68
    +34.00 (+0.48%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Regeneron stock rises, as profit, revenue and sales of SARS-CoV-2 antibody cocktail beat expectations

·1 min read
Regeneron stock rises, as profit, revenue and sales of SARS-CoV-2 antibody cocktail beat expectations
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Regeneron Pharmaceuticals Inc. rose 0.8% in premarket trading Thursday, after the biotechnology company beat first-quarter profit and revenue expectations, with sales of its REGEN-COV antibody cocktail to the SARS-CoV-2 virus also topping forecasts. Net income rose to $1.12 billion, or $10.09 a share, from $625 million, or $5.43 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew to $9.89 from $6.60, beating the FactSet consensus of $8.68. Revenue increased 38% to $2.53 billion, topping the FactSet consensus of $2.50 billion, as REGEN-COV sales of $262 million beat expectations of $254.6 million. For 2021, the company cut its capital expenditures guidance range to $585 million to $650 million from $600 million to $680 million. The stock has lost 3.3% over the past three months through Wednesday, while the iShares Nasdaq Biotechnology ETF has dropped 11.9% and the S&P 500 has gained 7.2%.